Victory Capital Management
CASI

Victory Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

Victory Capital Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,483
Closed -$6K – 2706
2022
Q1 		$6K Sell
1,483
-42
-3% -$330 ﹤0.01% 2697
2021
Q4 		$12K Buy
1,525
+78
+5% +$777 ﹤0.01% 2725
2021
Q3 		$17K Sell
1,447
-117
-7% -$1.58K ﹤0.01% 2736
2021
Q2 		$24K Buy
1,564
+88
+6% +$1.48K ﹤0.01% 2696
2021
Q1 		$35K Buy
1,476
+230
+18% +$6.46K ﹤0.01% 2691
2020
Q4 		$37K Buy
1,246
+202
+19% +$4.39K ﹤0.01% 2475
2020
Q3 		$16K Buy
+1,044
New +$19.7K ﹤0.01% 2444
2020
Q2 		– Sell
-751
Closed -$15K – 2625
2020
Q1 		$15K Buy
+751
New +$17.9K ﹤0.01% 2937
2019
Q4 		– Sell
-948
Closed -$32K – 2733
2019
Q3 		$32K Buy
+948
New +$30.4K ﹤0.01% 2877

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Victory Capital Management's CASI Position: Q2 2022 in Review

Victory Capital Management sold out of CASI Pharmaceuticals (CASI) in Q2 2022, closing a stake of 1,483 shares — an estimated $6K sold.

Victory Capital Management first reported a position in CASI in Q3 2019 and held it in 9 quarters. The position peaked at $37K in Q4 2020. 24 funds tracked by Wall St. Rank hold CASI as of Q2 2022.

  • Victory Capital Management reported no remaining CASI Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Victory Capital Management sold 1,483 CASI Pharmaceuticals shares in Q2 2022, an estimated $6K.
  • Victory Capital Management first reported a position in CASI Pharmaceuticals in Q3 2019 and held it in 9 quarters.
  • Victory Capital Management's CASI Pharmaceuticals position peaked at $37K in Q4 2020.
  • 24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2022.

Based on Victory Capital Management's 13F filing for Q2 2022, filed 1 Aug 2022.